Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
Oberschmidt
O
O
Allgemeines Krankenhaus St. Georg, Hamburg, Germany.
Eismann
U
U
Schulz
L
L
Struck
S
S
Blatter
J
J
Lahn
M M
MM
Ma
D
D
Hanauske
A R
AR
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology; D005971:Glutamates / Q000494:pharmacology*; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D000068437:Pemetrexed; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D064546:Protein Kinase C beta; D013964:Thyroid Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D005493:Folic Acid Antagonists; D005971:Glutamates; D007211:Indoles; D000068437:Pemetrexed; D006147:Guanine; D011493:Protein Kinase C; D064546:Protein Kinase C beta; C504878:enzastaurin